Safety and Efficacy Study for Reverse Flow Used During Carotid Artery Stenting Procedure

NCT ID: NCT01685567

Last Updated: 2017-07-07

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 219 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2012-11-30
• Study Completion Date: 2016-07-31

Brief Summary

The purpose of this study is to obtain and establish the safety and efficacy of The MICHI™ Neuroprotection System with Filter (MICHI™ NPS+f) for providing cerebral embolic protection during angioplasty and stenting procedures in carotid arteries. The MICHI NPS+f also facilitates access to the carotid and neuro anatomy for the introduction of therapeutic or diagnostic endovascular devices and/or agents. It will be used in conjunction with a FDA approved carotid artery stent for the treatment of carotid artery disease.

Detailed Description

Cerebral embolization during carotid artery stenting (CAS) can often precipitate severe adverse neurological effects. Most major clinical studies of CAS have used distal filters for cerebral protection and have compared the neurologic complication rates with those of carotid endarterectomy (CEA). Many currently available embolic protection devices, however, have limited efficacy in capturing microembolic debris that is liberated during stenting, pre-dilatation and post-dilatation. Distal protection systems are furthermore limited by the need to cross the lesion prior to deployment. Some studies have shown a relatively high incidence of cerebral infarction even when distal protection devices are employed.

Cerebral protection with carotid flow reversal is a method that was developed as an alternative to the use of distal protection devices. While novel in its approach, this method too has its limitations. Another technique developed employs carotid flow reversal prior to traversing the stenosis and can be accomplished by directly accessing the carotid anatomy without the use of the transfemoral approach. Major benefits to this method include a simpler route to the target lesion and the ability to perform the procedure on patients with severe carotid tortuosity and difficult aortic arch anatomy.

Conditions

Carotid Artery Disease

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: PREVENTION
• Blinding Strategy: NONE

Study Groups

MICHI NPS+f

The MICHI™ NPS+f is a flow reversal circuit consisting of two proprietary sheaths connected by standard surgical tubing. The sheaths each have a standard hemostasis valve and sidearm. An in-line flow regulator allows the clinician to modify to the flow through the circuit (either high flow or low flow) in addition to permitting temporary cessation of flow.

Group Type: EXPERIMENTAL

MICHI NPS+f

Intervention Type: DEVICE

Cerebral protection with carotid flow reversal

Interventions

MICHI NPS+f

Cerebral protection with carotid flow reversal

Intervention Type: DEVICE

Other Intervention Names

ENROUTE Transcarotid Neuroprotection System

Eligibility Criteria

Inclusion Criteria

1. Patient must meet one of the following criteria regarding neurological symptom status and degree of stenosis:

• Symptomatic: Stenosis must be greater than or equal to 50% as determined by angiogram and the patient has a history of stroke (minor or non-disabling), TIA and/or amaurosis fugax within 180 days of the procedure.
• Asymptomatic: Stenosis must be greater than or equal to 70% as determined by angiogram without any neurological symptoms within the prior 180 days.

2. Target vessel must meet diameter requirements for stent (refer to selected stent IFU for diameter requirements).

3. Patient has a discrete lesion located in the internal carotid artery (ICA) with or without involvement of the contiguous common carotid artery (CCA).

4. Patient is greater or equal to 18 years of age.

5. Patient has no childbearing potential or has a negative pregnancy test within one week prior to the study procedure.

6. Patient understands the nature of the procedure and has provided a signed informed consent using a form that has been reviewed and approved by the Investigational Review Board/Ethics Committee of the respective clinical site prior to the procedure. This will be obtained prior to participation in the study.

7. Patient is willing to comply with the protocol requirements and return to the treatment center for all required clinical evaluations.

8. Patient meets at least one of the anatomic or clinical high-risk criteria.

Exclusion Criteria

1. Patient has chronic atrial fibrillation.

2. Patient has had any episode of paroxysmal atrial fibrillation within the past 6 months, or history of paroxysmal atrial fibrillation requiring chronic anticoagulation.

3. Patient has an evolving stroke.

4. Patient has severe dementia.

5. Patient has a history of spontaneous intracranial hemorrhage within the past 12 months.

6. Patient has had a recent (<7 days) stroke of sufficient size (on CT or MRI) to place him or her at risk of hemorrhagic conversion during the procedure.

7. Patient had hemorrhagic transformation of an ischemic stroke within the past 60 days.

8. Patient has active bleeding diathesis or coagulopathy or will refuse blood transfusion.

9. Patient had or will have CABG, endovascular stent procedure, valve intervention or vascular surgery within 30 days before or after the intervention.

10. Patient has had a recent GI bleed that would interfere with antiplatelet therapy.

11. Life expectancy of < 12 months post procedure.

12. Patient has history of intolerance or allergic reaction to any of the study medications or stent materials (refer to stent IFU), including aspirin (ASA), ticlopidine, clopidogrel, prasugrel, statin or contrast media (that can't be pre medicated). Patients must be able to tolerate statins and a combination of ASA and ticlopidine, ASA and clopidogrel or ASA and prasugrel.

13. Myocardial Infarction within 72 hours prior to the intervention.

14. Presence of a previous placed intravascular stent in target vessel or the planned arteriotomy site.

15. Patient has had neurologic illnesses within the past two years characterized by fleeting or fixed neurologic deficit which cannot be distinguished from TIA or stroke (e.g. partial or secondarily generalized seizures, complicated or classic migraine, tumor or other space-occupying brain lesions, subdural hematoma, cerebral contusion or other post-traumatic lesions, intracranial infection, demyelinating disease, moderate to severe dementia, or intracranial hemorrhage).

16. Patient with a history of major stroke (CVA or retinal embolus) with major neurological deficit likely to confound study endpoints within 1 month of index procedure.

17. Patient has Hgb <10 g/dl, platelet count <125,000/μl, uncorrected INR >1.5, bleeding time >1 minute beyond upper limit normal, or heparin-associated thrombocytopenia.

18. Patient has an intracranial tumor.

19. Patient is actively participating in another drug or device trial (IND or IDE) that has not completed the required protocol follow-up period.

20. Patient has inability to understand and cooperate with study procedures or provide informed consent.

21. Occlusion or [Thrombolysis In Myocardial Infarction Trial (TIMI 0)] "string sign" >1cm of the ipsilateral common or internal carotid artery.

22. Patient has vertebrobasilar insufficiency symptoms only, without clearly identifiable symptoms referable to the study carotid artery.

23. Knowledge of cardiac sources of emboli.e.g. left ventricular aneurysm, intracardiac filling defect, cardiomyopathy, aortic or mitral prosthetic heart valve, calcific aortic stenosis, endocarditis, mitral stenosis, atrial septal defect, atrial septal aneurysm, or left atrial myxoma).

24. Recently (<60 days) implanted heart valve (either surgically or endovascularly), which is a known source of emboli as confirmed on echocardiogram.

25. Ostium of Common Carotid Artery (CCA) requires revascularization.

26. Presence of extensive or diffuse atherosclerotic disease involving the proximal common carotid artery that would preclude the safe introduction of the study device.

27. The patient has less than 5cm between the clavicle and bifurcation, as assessed by duplex Doppler ultrasound.

28. Bilateral carotid stenosis if intervention is planned within 37 days of the index procedure.

29. An intraluminal filling defect (defined as an endoluminal lucency surrounded by contrast, seen in multiple angiographic projections, in the absence of angiographic evidence of calcification) that is not associated with an ulcerated target lesion.

30. Abnormal angiographic findings: ipsilateral intracranial or extracranial arterial stenosis greater in severity than the lesion to be treated, cerebral aneurysm > 5 mm, AVM (arteriovenous malformation) of the cerebral vasculature, or other abnormal angiographic findings.

31. Patient has had a previous intervention in the ipsilateral proximal CCA.

32. Patient has had a TIA or amaurosis fugax within 48 hours prior to the procedure.

33. Patient has contralateral lateral recurrent, laryngeal or vagus nerve injury.

34. Patient is otherwise unsuitable for intervention in the opinion of the investigator.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Silk Road Medical

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Christopher Kwolek, MD

Role: PRINCIPAL_INVESTIGATOR

Massachusetts General Hospital

Richard Cambria, MD

Role: PRINCIPAL_INVESTIGATOR

Massachusetts General Hospital

Locations

Peter Morton UCLA Medical Center

Los Angeles, California, United States

Florida Hospital

Orlando, Florida, United States

Johns Hopkins Bayview Medical Center

Baltimore, Maryland, United States

Massachusetts General Hospital

Boston, Massachusetts, United States

University of Michigan Medical Center

Ann Arbor, Michigan, United States

McLaren Regional Medical Center

Flint, Michigan, United States

Washington University School of Medicine

St Louis, Missouri, United States

Albany Medical Center

Albany, New York, United States

University at Buffalo Neurosurgery, Inc

Buffalo, New York, United States

Columbia University

New York, New York, United States

Cleveland Clinic Foundation

Cleveland, Ohio, United States

University Hospitals Case Medical Center and Case Western Reserve University School of Medicine

Cleveland, Ohio, United States

Riverside Methodist Hospital

Columbus, Ohio, United States

Jobst Vascular Institute

Toledo, Ohio, United States

Oklahoma Heart

Oklahoma City, Oklahoma, United States

Greenville Hospital System

Greenville, South Carolina, United States

Cardiothoracic & Vascular Surgeons

Austin, Texas, United States

Methodist Medical Center

Dallas, Texas, United States

Dallas VA Medical Center

Dallas, Texas, United States

Sentara Vascular Specialists

Norfolk, Virginia, United States

Hospital Virgen de la Salud

Toledo, , Spain

Countries

United States; Spain

References

Kwolek CJ, Jaff MR, Leal JI, Hopkins LN, Shah RM, Hanover TM, Macdonald S, Cambria RP. Results of the ROADSTER multicenter trial of transcarotid stenting with dynamic flow reversal. J Vasc Surg. 2015 Nov;62(5):1227-34. doi: 10.1016/j.jvs.2015.04.460.

Reference Type: RESULT

PMID: 26506270 (View on PubMed)

Alpaslan A, Wintermark M, Pinter L, Macdonald S, Ruedy R, Kolvenbach R. Transcarotid Artery Revascularization With Flow Reversal. J Endovasc Ther. 2017 Apr;24(2):265-270. doi: 10.1177/1526602817693607. Epub 2017 Feb 17.

Reference Type: RESULT

PMID: 28335706 (View on PubMed)

Chung J, Kumins NH, Smith J, Motaganahalli RL, Schneider PA, Kwolek CJ, Kashyap VS; ROADSTER Investigators. Physiologic risk factors increase risk of myocardial infarction with transcarotid artery revascularization in prospective trials. J Vasc Surg. 2023 Apr;77(4):1192-1198. doi: 10.1016/j.jvs.2022.12.013. Epub 2022 Dec 20.

Reference Type: DERIVED

PMID: 36563712 (View on PubMed)

Malas MB, Leal Lorenzo JI, Nejim B, Hanover TM, Mehta M, Kashyap V, Kwolek CJ, Cambria R. Analysis of the ROADSTER pivotal and extended-access cohorts shows excellent 1-year durability of transcarotid stenting with dynamic flow reversal. J Vasc Surg. 2019 Jun;69(6):1786-1796. doi: 10.1016/j.jvs.2018.08.179. Epub 2019 Jan 2.

Reference Type: DERIVED

PMID: 30611582 (View on PubMed)

Related Links

https://www.ncbi.nlm.nih.gov/pubmed/?term=26506270

Results of the ROADSTER multicenter trial of transcarotid stenting with dynamic flow reversal.

https://www.ncbi.nlm.nih.gov/pubmed/28335706

Transcarotid Artery Revascularization with Flow Reversal: the PROOF Study

Other Identifiers

SRM-2012-02

Identifier Type: -

Identifier Source: org_study_id